US appeal court denies plea for Myblu to remain on sale during MDO challenge

Myblu vaping products will not be allowed to be sold in the US market while a court reviews a marketing denial order (MDO).

An appeal court has declined to issue an emergency stay for Fontem US in its challenge to an MDO issued by the US Food and Drug Administration (FDA). The decision is a defeat for the maker of the Myblu vaping pod that could have greater implications for it as it pursues its full court challenge, with a panel of three judges determining that it “has not made a strong showing that it is likely to succeed on the merits”.

Read full article
I'm already a subscriber
Author default picture


This article was written by one of ECigIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual vaping markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global e-cigarette market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

ECigIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization